News

ADVANCE develops the Blueprint

01/11/2018

The ADVANCE project was created in response to the 2009 A(H1N1) influenza pandemic which highlighted that in Europe there were several factors limiting the collaboration of the key stakeholders to collectively assess vaccine safety and effectiveness.

The ADVANCE vision has been to deliver “Best evidence at the right time to support decision-making on vaccination in Europe”, and its mission has been to establish a prototype of a sustainable and compelling framework to support the rapid provision of best available scientific evidence on post-marketing vaccination benefits and risks for well informed decisions.

After five years the project has managed to deliver a Blueprint document based on the project outputs, summarizing methods, infrastructure, scenarios and sustainability for conducting different types of studies related to post-marketing vaccine coverage, benefit and risk monitoring. The ADVANCE Blueprint, written by ECDC, has undergone a broad stakeholder and public consultation.